Across TCGA pan-cancer cohorts, SYT1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SYT1 data layer compared with 20 for mass-spec protein and 4 for mutation status.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SYT1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SYT1 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.
HNSC, LUAD, and GBM are the cancer types where SYT1 mass-spec protein most reproducibly stratifies survival.